This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): fulvestrant
Description: Faslodex (Fulvestrant) is an estrogenreceptor antagonist that binds to the estrogen receptor in a competitivemanner with affinity comparable to that of estradiol. Fulvestrantdownregulates the ER protein in human breast cancer cells.
Pink Sheet Faslodex FDA Reviewers
Pink Sheet Faslodex Clinical Protocols
Pink Sheet Faslodex Clinical Development
Additional information available to subscribers only: